Centre Hospitalier Saint Nazaire
- Address
- lock Available on a paid plan
Oncology and Hematologic Malignancies
At Centre Hospitalier Saint Nazaire, the medical oncology program includes studies in neoplasms, with a strong focus on breast cancer, head and neck squamous cell carcinoma, multiple myeloma, and follicular lymphoma. These trials are mainly designed to evaluate new treatment approaches, compare combination strategies, and improve disease control and survival.
- Testing new treatment combinations for recurrent, metastatic, and locally advanced head and neck cancers
- Evaluating maintenance and relapse strategies in multiple myeloma
- Studying targeted and immune-based options for follicular lymphoma
- Assessing personalized therapy choices in early and high-risk breast cancer
Overall, this research area centers on improving effectiveness, extending survival, and refining treatment selection for patients with complex cancers.
Blood Disorders and Immune Conditions
Clinical research also covers hemic and lymphatic diseases and immune system diseases, including immune thrombocytopenia, myelodysplastic syndromes, and related inflammatory or bleeding disorders. The purpose of these trials is to compare supportive and disease-directed treatments, while seeking safer and more effective ways to manage symptoms and long-term outcomes.
- Improving treatment options for adults with persistent or chronic immune thrombocytopenia
- Studying better timing of therapy in low-risk myelodysplastic syndrome
- Exploring new immune-modulating strategies for blood-related disorders
- Evaluating treatment effectiveness and response durability in hematology care
This portfolio reflects a broad interest in balancing efficacy, safety, and quality of life for patients with chronic hematologic conditions.
Cardiovascular and Cerebrovascular Research
Trials in cardiovascular diseases and nervous system diseases include conditions such as stroke, intracerebral hemorrhage, transient ischemic attack, myocardial infarction, and atherosclerosis. These studies aim to improve prevention and treatment strategies, reduce complications, and support better recovery after major vascular events.
- Assessing approaches to reduce risk after intracerebral hemorrhage
- Evaluating long-term prevention of recurrent vascular events
- Studying treatments for stroke and other ischemic brain injuries
- Improving care for patients with coronary syndrome and related heart disease
These projects focus on practical ways to lower recurrence, improve outcomes, and support recovery in patients with serious cardiovascular and neurological disease.
Infectious and Respiratory Disease Studies
The site contributes to research in bacterial infections and mycoses as well as respiratory tract diseases, with studies involving community-acquired pneumonia and bartonellosis. The main goal is to compare treatment choices and determine whether simpler or more targeted therapy can provide similar clinical benefit.
- Comparing antibiotic strategies for older adults with community-acquired pneumonia
- Investigating treatment options for bartonellosis and related lymph node infection
- Supporting better antimicrobial use in routine hospital care
- Exploring effectiveness while limiting unnecessary treatment exposure
These studies reflect a focus on improving everyday infectious disease care through more precise and effective treatment decisions.
Surgical, Supportive, and Symptom-Relief Research
Another area of activity involves anesthesia and analgesia, along with supportive care for conditions such as hemorrhoidal disease and postoperative discomfort. Trials in this field are designed to improve comfort, pain control, and recovery in the hospital setting.
- Evaluating methods to reduce postoperative pain and discomfort
- Studying symptom relief during critical care recovery
- Improving patient comfort after procedures for hemorrhoids
- Testing supportive approaches that may enhance recovery experience
At Centre Hospitalier Saint Nazaire, these studies emphasize patient-centered care by focusing on comfort, recovery quality, and practical symptom management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 59 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 55 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Saint Nazaire
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Combined with Chemotherapy versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2) | Regeneron Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 59 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 3 | Unknown | 2015-06-26 | 2026-06-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.